

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application
Serial No. : 09/877,341

Applicant: : Gerald B. Eaton, et al.

Filed : June 8, 2001

Title: : DRAG REDUCING AGENT SLURRIES HAVING ALFOL ALCOHOLS AND
PROCESSES FOR FORMING DRAG REDUCING AGENT SLURRIES USING
ALFOL ALCOHOLS

TC/A.U. : 1764


Examiner : Ellen M. McAvoy

Docket No. : 86821

**FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98**

BOX NON-FEE AMENDMENT
Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:



In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Fifth Supplemental Information Disclosure Statement be entered and the reference listed on attached Form PTO-1449 be considered by the Examiner and made of record. A copy of the reference listed on Form PTO-1449 is enclosed for the convenience of the Examiner.

This Fifth Supplemental Information Disclosure Statement is being filed after a first Office Action on the merits, but before the mailing date of any of a final action under 37 C.F.R. § 1.113,


HOU:2344134.1

a notice of allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution in the application. Additionally, no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in this Fifth Supplemental Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Fifth Supplemental Information Disclosure Statement. Accordingly, Applicant submits that this Fifth Supplemental Information Disclosure Statement should be considered in accordance with 37 C.F.R. § 1.97(c)(1) and no fee is required. However, in the event that a fee is required for this Fifth Supplemental Information Disclosure Statement, the Commissioner is authorized to charge the fee, (or credit any over payment) to Account No. 50-0897, Order No. 86921/AFM.

In accordance with 37 C.F.R. §§ 1.97(g) and (h), this Fifth Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is material to patentability as defined in 37 C.F.R. § 1.56(a). The submission of the following information should not necessarily be deemed a concession that any particular item constitutes "prior art" to the claimed invention.

Respectfully submitted,

Date: 4/3/2003



Anthony F. Matheny
Reg. No. 43,778
Customer No. 31248
Andrews & Kurth L.L.P.
600 Travis, Suite 4200
Houston, Texas 77002
(713) 220-4168
(713) 238-7260 (fax)
Attorney for Assignee

HOU:2244224.1

FORM 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/877,341
	Filing Date	June 8, 2001
	First Named Inventor	Gerald B. Eaton
	Group Art Unit	1764
	Examiner Name	Ellen M. McAvoy
	Attorney Docket Number	86821

Sheet 1 of 1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	KA	4,142,991		Arzoumanidis et al.	03-06-1979

FOREIGN DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation?
		Office	Number	Kind Code (if known)			

OTHER DOCUMENTS			
Examiner Initials*	Cite No.	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation?

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
HOU2144112.1